Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018

Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimer's Disease Candidate

Avid Bioservices Announces Resignation of Chief Financial Officer

Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences

Avid Bioservices Announces Closing of Public Offering of Common Stock

Avid Bioservices Announces Pricing of Public Offering of Common Stock

Avid Bioservices Announces Proposed Offering of Common Stock

Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid's PS-Targeting Program Including Bavituximab

Avid Bioservices to Present at NobleCon14

Peregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development and Manufacturing Organization (CDMO)